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Background: Urokinase plasminogen activator (uPA), its receptor uPAR and serine 
protease inhibitors PAI-1 or PAI-2 play key roles in tissue membrane remodeling and 
invasion of basement membranes by induction of a fibrinolytic pathway. Earlier studies 
reported that uPA and PAI-1 protein levels in breast carcinomas assist in prediction of 
response to chemotherapy. Our goal is to develop molecular signatures of candidate 
genes and identify novel relationships with these four protein biomarkers that 
demonstrate clinical utility for assessment of breast carcinoma outcomes. 
Methods: This retrospective study used de-identified biomarker results and clinical 
outcomes from primary breast cancers that were stored in an IRB-approved Database. 
ELISA analyses of uPA, uPAR and PAI-1 performed using IMUBIND kits (American 
Diagnostica Inc.) used cutoff values previously reported. Estrogen (ER) and progestin 
receptor (PR) assays were performed either by EIA (Abbott Labs) or by radioligand 
binding (NEN/DuPont). Relative expression levels of 22,000 genes were determined by 
microarray using RNA extracted and amplified from Laser-Capture Microdissection (LCM) 
procured breast carcinoma cells. Violin plots, scatter grams, univariable Cox regression 
and survival analyses were performed by R Studio version 3.4.1. 
Results: Patient age was not significantly associated with level of either uPA, uPAR or 
PAI-1 protein, while Violin plots showed protein content of biomarkers was related to 
either ER or PR status of the primary. Examination of expression revealed that either ER- 
or PR- breast cancers expressed elevated levels of uPA, uPAR and PAI2 genes 
compared to that of ER+ or PR+ carcinoma cells. Scatter plots revealed inverse 
relationships between ER/PR protein levels and expression of uPA, uPAR and PAI-2, 
whereas HER2 status was unrelated to either protein content or gene expression for each 
relationship examined. Interrelationships analysis revealed an elevation of uPAR content 
in pre-menopausal cancer and increased PAI-1 expression in node negative cancers. 
When carcinomas were sorted by urokinase biomarker levels, qPCR expression of RERG 
and NQO-1 genes were elevated in uPA- lesions while CD34 and EDG-1 genes were 
elevated in uPAR- cancers. However, ERBB4 gene expression was elevated in PAI-1+ 
carcinomas. Furthermore, Cox regression analyses revealed relationships of ER/PR 
status and uPA system members with regard to clinical outcomes of breast cancer. 
Conclusions: Expression of either uPA, uPAR, PAI1 or PAI2 genes was significantly 
elevated in either ER- or PR- carcinomas similar to observed elevation of protein content 
in ER-/PR- carcinomas, strongly suggesting relationships between sex-hormone activity 
and regulation of urokinase plasminogen activator system in breast cancer. This was 
supported by results showing protein content of uPA system members was related to 
ER/PR status of the primary lesion. Use of LCM-procured breast carcinoma cells 
uncovered relationships between expression of several known cancer-associated genes 
and protein content of uPA system members. Collectively, results indicate evaluation of 
ER and PR protein of the primary breast cancer biopsy combined with analyses of uPA, 
uPAR and PAI-1 protein content improve assessment of clinical outcomes. 
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1  |  Introduction  
 
Current Status and Molecular Approaches for Management of Breast Carcinoma 
 
Significant advancements in screening and detection methods as well as the use 
of genomic profile testing and design of novel therapeutics in recent decades (e.g., [1, 2]) 
have improved personalized treatment options for patients with breast carcinomas. 
However, vast challenges remain regarding early screening, treatment of receptor 
negative subtypes and understanding the mechanisms of cancer metastasis [3, 4]. The 
development of antibody conjugated nanoparticles [5, 6], treatment regimens [7] and 
utilization of biomarkers [8] hold great promise for improving the management of breast 
cancer in the decades to come.  
Conventional Biomarkers Used in the Management of Breast Cancer  
 The standard of care for the management of breast cancer includes the 
assessments of levels of ER, PR and HER2 protein in the tissue biopsy (e.g., [9-11]). For 
instance, patients with breast cancers exhibiting a biomarker subtype of ER+/PR+/HER2- 
typically have a better prognosis and those patients with a biomarker subtype of 
ER+/PR+/HER2+  are candidates for hormonal treatments (e.g. Tamoxifen, Letrazole) as 
well as treatment with Herceptin or other humanized antibody based therapies whereas 
patients with triple negative breast cancers have poor survival and few treatment options 
other than chemotherapy, radiation and surgical excision of cancers (e.g., [10, 12-15]). 
Clinically relevant cut-off values for assays, which quantified the biomarkers, were 
established previously for each receptor that indicated potential for response to drug 
therapy regimens (e.g., Tamoxifen, Herceptin).  Within the past three decades, the 
principal assays for the three analytes have been semi-quantitative, 
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immunohistochemical-based procedures. Due to the lack of assay standardization and 
related problems, the College of American Pathologists (CAP) and the Society for Clinical 
Oncology (ASCO) established Guidelines for improving uniformity of measurements and 
reporting of IHC results [10, 15, 16]. 
 Although conventional biomarkers (e.g., ER, PR and HER2 proteins) have 
demonstrated utility in management protocols of breast cancer, improvements in personal 
treatment plans are at the forefront of cancer research. Genomic screens (e.g., gene 
expression profiles) have been developed which assess expression levels for genes 
whose actions and protein products are associated with breast cancer behavior. For 
instance, an FDA-approved microarray test known as MammaPrintTM uses expression of 
70 genes to assess risk of breast cancer development and risk of recurrence ([17-19], 
website: https://www.agendia.com/our-tests/mammaprint/). 
Review of Plasminogen Activator System and its Role in Cancer Behavior  
 A ubiquitous system known as the urokinase plasminogen activator (uPA) system 
is a proteolytic enzyme system consisting of 4 gene members, which collectively remodel 
tissue basement membranes (e.g., [20, 21]). The system consists of urokinase 
plasminogen activator (uPA), which is a serine protease, its respective uPA receptor 
(uPAR) which is associated with the extracellular components of a target cell, and two 
inhibitors of uPA association with uPAR (PAI-1 and PAI-2). One of the principal functions 
of the uPA system is to convert plasminogen to plasmin to aid in the dissolution and 
breakdown of fibrin at clot sites in blood vessels. In addition to the dissolution of clots, the 
uPA system also has reported roles in a range of biochemical processes such as control 
of inflammation, angiogenesis, embryogenesis, wound healing and cellular apoptosis 
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[22]. From a clinical standpoint, the uPA system is widely documented in processes of 
tumor migration, angiogenesis ([23, 24]), modulation of tumor microenvironments and 
metastasis in a number of cancers such as lung [25], breast (Harbeck et al. 2017), ovarian 
[26, 27], endometrial [27] and pancreatic [28]. However, it is critical to consider that 
reports of the efficacy of uPA system members as prognostic markers in other cancers 
(i.e., other than in breast carcinomas) remain contradictory [29].  
 The role of the uPA system in ECM degradation and cellular migration was first 
summarized by literature reviews in the context of proposed mechanisms leading to 
cancer metastasis [23, 30, 31]. Following early reports, extensive studies in vitro that 
utilized migration assays revealed that the uPA system directly regulates the rate of 
cellular migration. For instance, it was observed that expression of uPA, uPAR and PAI-
1 was up-regulated in human cancer lines wherein uPA and uPAR protein was 
concentrated at cellular perimeters [32-34]. Preliminary findings warranted further 
investigations of the presence of uPA system members in ECM invasion. Numerous 
findings revealed that the enzymatic activity of uPA was significantly decreased when 
cells were treated with antibodies and delayed ECM invasion was observed. Collectively, 
the role of uPA system members in cancer migration was substantiated by 
comprehensive studies in vivo.  
The translation for findings of studies with cells in culture and from experimental 
animal models to human cancer remains a challenge for researchers and clinicians. Thus, 
early studies were conducted to analyze expression or content of uPA, uPAR, PAI-1 and 
PAI-2 proteins in relation to the prognosis and survival of human breast cancer patients. 
Reviews by Duffy [35, 36] reported that uPA protein content was significantly elevated in 
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malignant breast lesions relative to that of benign or normal breast tissues.  Subsequent 
investigations of uPA demonstrated it could be used as a single prognostic marker for 
human breast cancer [37]. The utility of the uPA system as biomarkers was expanded by 
studies that found uPA protein content of a breast cancer served as a strong predictor of 
prognosis equal to that of nodal status and more predictive than either estrogen receptor 
or Cathepsin D levels [38-40]. Additional studies revealed correlations of PAI-1 protein 
content with cancer aggressive behavior and clinical outcomes (e.g., [38]) as well as the 
utility of uPA/PAI-1 protein levels when used in conjunction with PAI-1 as a prognostic 
marker.  
Clinical Application of the uPA System 
 The uPA system has been studied regarding cancer outcomes for nearly three 
decades, with one of the first suggestions for use as a prognostic marker by Duffy (cf. 
[20]). Following the original report of Duffy [41], multiple studies [29, 38, 40] demonstrated 
use of uPA/PAI-1 expression levels as predictors of cancer outcomes in node-negative 
breast cancer. At the turn of the millennium, large investigations confirmed the use of 
quantified uPA and PAI-1 from breast cancer patients as a measure for assessment of 
treatment response, progression and outcome [42-44]. Furthermore, breast cancers 
exhibiting high uPA/PAI-1 levels are associated with patients with poor prognosis, yet are 
most responsive to adjuvant chemotherapy [40, 45]. Additionally, patients having high 
uPA/PAI-1 levels in node negative breast cancers that are ER+ positive may benefit from 
anti-HER2 therapy in HER2+ breast cancer patients. Currently, the American Society of 
Clinical Oncology (ASCO) encourages medical oncologists to utilize quantified uPA/PAI-
1 levels in patients to direct decisions regarding adjuvant chemotherapy in early-stage 
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and node-negative breast cancers [46]. A major question remaining was related to the 
relationships of either uPA, PAI-1 or uPAR protein content in the context of the estrogen 
receptor (ER) or progestin receptor (PR) status of the primary breast carcinoma. 
Goals and Focus of Thesis Research 
The goals of translational research in the Hormone Receptor Laboratory include 
the development and application of scientific discoveries in the laboratory to precision 
medicine for improving clinical management of cancer patients. The original 
investigations reported, using extensive data mining approaches of existing databases in 
my mentor’s laboratory, are focused on relationships of the protein content of the 
biomarkers, uPA, uPAR and PAI-1 in primary breast cancer biopsies with other clinical 
features of the carcinomas (e.g., nodal status) and of the patients (e.g., menopausal 
status) to determine if there are alternative biomarker combinations (e.g., with either ER 
or PR status) that better predict clinical outcomes breast cancer. In addition, I extracted 
previously reported gene expression results obtained via microarray of RNA extracted 
from LCM-procured breast carcinoma cells (e.g., [46-52]) to compare with clinical 
outcomes and carcinoma-based parameters for the study populations of breast cancer 
patients. I am reporting expanded analyses of retrospective studies of de-identified 
biomarker results and de-identified clinical outcomes that were collected previously and 
stored in comprehensive databases established previously by my mentor. Investigations 
described here showing the combined clinical value of ER and PR determinations of the 
primary breast cancer biopsy with those for uPA, uPAR and PAI-1 protein content are an 
extension of an earlier report from our laboratory [53].  
Unique Parameters of These Investigations 
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Each assay of either uPA, uPAR or PAI-1 protein content was performed 
previously in the presence of a reference specimen developed specifically for Quality 
Assurance of analyses of these biomarkers (e.g., [26, 27, 53, 54]). Furthermore, protein 
content of either ER, PR or HER2, conventional biomarkers used in breast carcinoma 
clinical management (e.g., [9, 11]) were quantified previously using FDA or state of the 
art methods in the presence of reference specimens (e.g., refs 11, 57, 59, 60). Gene 
expression measurements, collected earlier, were performed with RNA extracted from 
LCM procured breast carcinoma cells in a non-destructive manner (e.g., [55]), without the 
interference of normal cellular components (e.g., stromal cells). The final analyses have 
been to correlate levels and distribution of uPA, uPAR and PAI-1 protein expression in 
primary breast cancer biopsies with expression of genes of interest in relationship to 
clinical outcomes. Dr. Wittliff and I will prepare the data in such a way that results will be 
available for use in the design of new clinical trials evaluating the prognostic significance 
of combinations of the analytes, uPA, uPAR and PAI-1, with ER, PR and HER2 protein 
levels. 
 
2  |  Materials & Methods  
 
REMARK  
 Summaries of patient and specimen characteristics are displayed by REMARK 
tables [56] for the two distinct populations analyzed in this study. The first patient 
population summary provided in Table 1 represents those patients whose tissue biopsy 
measurements of uPA, uPAR and PAI-1 were used in the investigations outlined in the 
Results Section. Protein biomarker measurements were performed by earlier 
investigators in the laboratory according to the protocols described for determination of 
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urokinase plasminogen activator system members [26, 27, 54]. A summary of patient 
characteristics and tissue-based measurements for the population used in the microarray 
studies is given in Table 2. Patients were treated with standard of care of time of tissue 
biopsy collection and tissue measurements were performed according the protocols 

































Table 1. Clinico-pathological properties of study population of primary breast 




































aCutoff values for ER and PR are described in the methods. bCutoff values for HER2 protein levels for the 
NEN/DuPont ELISA was 1.7 hnu/g protein, while that used for the TRITON Diagnostics EIA was 129.9 hnu/mg 
protein. 
 
Continuous Variables Mean (sd)  
Age (yrs) 55.0 (14.5) 
Tumor Size (mm) 29.8 (14.6) 
  Median (IQR) 
Progression Free Survival (mos) 52 (2–77) 
Overall Survival (mos) 62.5 (33–78) 
Discrete Variables n (%) 
Menopausal Status (n=749)  
                   Premenopausal 359 (47.9) 
Postmenopausal 386 (51.5) 
Unknown 4 (0.6) 
Biomarker Measurements (protein)   
                         uPA 745 
                         uPAR           616 
                         PAI-1 749  
PFS Events 11 (10.0) 
PFS Censored 99 (90.0) 
OS Events 27 (24.5) 
OS Censored 83 (75.5) 
Pathology of Primary  
 IDC 80 (76.2) 
ILC 7 (6.7) 
IDC + ILC 1 (1.0) 
Other Histologic Types 17 (16.2) 
Nodal Status (n=105)  
                             N 0 48 (45.7) 
N 1–3 27 (25.7) 
N >3 17 (16.2) 
unknown 13 (12.4) 
Tumor Grade (n=105)  
1 10 (9.5) 
2   32 (30.5) 
3   38 (36.2) 
4   2 (1.9) 
unknown   23 (21.9) 
Tumor Stage (n=105)  
0 4 (3.8) 
1 26 (24.8) 
2 50 (47.6) 
3 9 (8.6) 
4 9 (8.6) 
unknown 7 (6.7) 
Steroid Receptor Status (n=498)a  
ER+ 263 (52.8) 
ER– 235 (47.2) 
PR+ 271 (54.4) 
PR– 227 (45.6) 
HER2 status (n=425)  
HER2+  254 (59.8) 
                           HER2–  171(40.2) 
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Table 2. Clinico-pathological properties of microarray study population of primary breast 



























aCutoff values for ER and PR are described in the methods. bCutoff values for HER2 protein levels for the 
NEN/DuPont ELISA was 1.7 hnu/g protein (7+ of 14 biopsies), while that used for the TRITON Diagnostics EIA was 
129.9 hnu/mg protein (21+ of 31 biopsies). 
Continuous Variables Mean (sd)  
Age (yrs) 58.4 (14.9) 
Tumor Size (mm) 29.8 (16.3) 
  Median (IQR) 
Progression Free Survival (mos) 57 (26.0–82.5) 
Overall Survival (mos) 65 (41.0–89.5) 
Discrete Variables n (%) 
Menopausal Status  
                   Premenopausal   58 (23.5) 
Postmenopausal 135 (54.6) 
Unknown   54 (21.9) 
Race  
                         White 211 (85.4) 
                         Black        34 (13.8) 
                         Other   2 (0.8) 
PFS Events   96 (38.9) 
PFS Censored 151 (61.1) 
OS Events   75 (30.4) 
OS Censored 172 (69.6) 
Pathology of Primary  
IDC 201 (81.4) 
ILC 15 (6.1) 
IDC + ILC   2 (0.8) 
Other Histologic Types   29 (11.7) 
Nodal Status  
N 0 126 (51.0) 
N 1–3   55 (22.3) 
N >3   46 (18.6) 
unknown 20 (8.1) 
Tumor Grade  
1 14 (5.7) 
2   69 (27.9) 
3   94 (38.1) 
4   1 (0.4) 
unknown   69 (27.9) 
Tumor Stage  
0 3 (1.2) 
1 60 (24.3) 
2     140 (56.7) 
3 35 (14.2) 
4 4 (1.6) 
unknown 5 (2.0) 
Steroid Receptor Statusa  
ER+ 146 (59.1) 
                             ER– 101 (40.9) 
PR+ 151 (61.1) 
                             PR–   96 (38.9) 
HER2 status (n=45)b  
HER2+ 28 (62.2) 
HER2– 17 (37.8) 
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Determination of plasminogen activator system biomarkers 
 
 ELISA analyses previously quantified uPA, uPAR and PAI-1 levels using 
IMUBIND kits (formerly American Diagnostica Inc., Greenwich, CT; currently BioPacific 
Diagnostics, Inc., Bellevue, WA) applying cutoff values previously reported [38]. Cutoff 
values of 3.0, 2.9 and 2.2 ng/mg protein were utilized for protein measurements of 
biomarkers uPA, uPAR and PAI-1, respectively. Biomarker cutoff values for uPA and PAI-
1 were determined in accordance with clinically defined parameters [38], whereas the 
cutoff value that I employed for uPAR protein was the median of 614 measurements from 
the patient population. Kits for assessing PAI-2 protein were unavailable at the time of 
these analyses.  
 Biochemical analyses of uPA, uPAR and PAI-1 were performed as described 
previously [26, 27, 53, 54] using a sandwich ELISA procedure (IMUBIND, American 
Diagnostica Inc., Greenwich, CT; currently BioPacific Diagnostics, Inc., Bellevue, WA). 
The uPA assay recognizes pro-uPA, high molecular-weight uPA, receptor-bound uPA 
and uPA complexed with PAI-1 and PAI-2. With the uPAR assay, both soluble and native 
(membrane-associated) uPAR as well as complexes of either uPAR/uPA or 
uPAR/uPA/PAI-1 are all recognized. The PAI-1 assay determined both active and inactive 
forms of free PAI-1 and PAI-1 complexes according to the manufacturer [53, 54]. The 
final concentration of each analyte was expressed in ng of uPA, uPAR or PAI-1 per mg 
extract protein.           
Determination of estrogen receptor and progestin receptor protein levels 
 Estrogen receptor and progestin receptor protein levels were determined 
previously using either the Abbott Laboratories (North Chicago, IL) enzyme immunoassay 
 18 
(EIA kit) or the radio-labeled ligand binding assay (NEN/DuPont kit, Wilmington, DE) on 
freshly prepared cytosols as described previously [9, 11, 57, 58]. Using the latter FDA-
approved kits which employ either [3H]estradiol-17β or [3H]R5020 depending upon the 
receptor type being determined, specific ligand binding capacity, reflecting both receptor 
level, expressed as fmol/mg cytosol protein, and activity expressed as the apparent 
dissociation constant (Kd value as M) were determined previously by Scatchard analysis. 
Determination of ER and PR levels by EIA employed an FDA-approved kit formerly 
distributed by Abbott Laboratories [11, 57]. The distribution according to ER and PR 
status of the primary breast carcinomas used in my investigations is given in Tables 1 
and 2.  
Detection of HER2/neu in primary breast cancers Seth  
 HER2/neu oncoprotein status was measured in primary breast carcinomas using 
either one of the two experimental antibody-based assays as described previously [11, 
54, 59, 60]. Cutoff values measured in HER2-neu units (hnu) utilized for NEN/DuPont 
ELISA (which became Oncogene Science Diagnostics) was 1.7 hnu/µg protein (7+ of 14 
biopsies), while that used for the TRITON Diagnostics EIA was 129.9 hnu/mg protein (21+ 
of 31 biopsies).   
Assessment of gene expression in LCM-procured cells using microarray analyses  
 Results described in my investigations were collected previously from de-identified 
primary breast cancer carcinomas obtained from 1988 – 1996, in IRB-approved studies 
and stored in de-identified databases of the Hormone Receptor laboratory which holds 
CLIA and Commonwealth of Kentucky licenses [48, 49, 51, 52, 55]. Selection and 
examination of the patient population were performed using REMARK criteria [1] as 
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described previously [47-50, 52, 61]. Patients were treated with standard of care at time 
of diagnosis. Patient-related characteristics and tissue-based properties (Table 1), stored 
as de-identified parameters in our unique comprehensive databases were explored to 
determine relationships between relative gene expression and clinical parameters.  
 Briefly, tissue sections of frozen de-identified tissue biopsies were processed 
previously for Laser Capture Microdissection (LCM) with a PixCell IIe™ Instrument 
(Arcturus/Thermo Fisher), as described previously [48, 49, 51, 52, 55, 58]. As reported 
earlier [55, 62, 63], total RNA was extracted from LCM-procured cells and amplified  
before microarray as described earlier. Relative expression levels of each of 22,000 
genes obtained from microarray uniquely represented only those mRNA species of breast 
carcinoma cells [49, 51, 55, 58, 62, 63]. 
Assessment of gene expression in breast carcinoma tissue sections using qPCR 
analyses 
 Using qPCR results determined in our laboratory by other investigators [48, 49, 51, 
52, 64], gene expression levels for 110 genes, known to be associated with various 
cancers, were used in my studies to explore relationships with members of the urokinase 
plasminogen activator system.   
Univariable Cox regression and Kaplan-Meier Analyses    
Statistical computations, violin plots and Kaplan-Meier plots were performed using 
R version 3.2.5. Utilizing commands from R package survival [65] univariable Cox 
regressions of expression levels of each gene candidate estimated p-values of hazard 
ratios (HR) to determine genes suggesting clinical significance. P-values were adjusted 
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for multiple comparisons using the Benjamini and Hochberg (BH) method with <0.30 
selected as the “discovery” cutoff as applied earlier [47, 66-68].   
 Univariable Cox regression was performed on each gene candidate using relative 
expression levels to discern relationships with Progression Free Survival (PFS) and 
Overall Survival (OS). This allows the use of relative gene expression values as a single 
covariate to investigate extent to which expression levels of a single gene in the cohort 
predicted PFS or OS of breast cancer patients. Hazard ratios were derived from 
univariable Cox regression models and calculated for each of the candidate genes.  
Relative gene expression levels determined with LCM-procured carcinoma cells 
from 247 patients were stratified above and below the median for each univariable 
significant gene candidate. Adjusted p-values (BH method) were derived from Log-Rank 
Tests comparing survival times between groups. Since ER and PR status of a breast 
cancer is related to a patient’s prognosis [10, 11, 47, 48, 58], analyses of candidate gene 
expression in LCM procured cells according to steroid hormone receptor status of the 
primary carcinoma biopsy were performed. Survival curves for various groups were 
visualized in Kaplan-Meier plots with the number of patients at risk at various time points 
displayed in a table below each plot.  
 
3  |  Results 
 
3.1  |  Interrelationships of biomarker protein status of the primary breast carcinoma 
as a function of patient age 
 
 Scatter plots were constructed in order to ascertain the relationship between 
patient age and quantified biomarker protein in the primary breast cancer (Figure 1). 
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Linear regression analyses were performed and a p-value of < 0.05 was considered 
significant. Our results indicated that age of the patient was not significantly associated 
with the level of either uPA, uPAR or PAI-1 biomarker protein in the primary breast cancer.  
 
Figure 1. Scatter plots analyses of patient age versus protein biomarker content of 
members of the urokinase plasminogen activator system. a) Relationship of age versus 
[uPA], n=217 ; b) Age versus [uPAR], n=218 ; c) Age versus [PAI-1], n=218 
 
3.2  |  Determinations of biomarker protein status as a function of either ER or PR 
protein status of the primary breast carcinoma  
 
 Violin plots were computed of biomarker protein content (ng biomarker/mg total 
protein) of each uPA system member according to either ER or PR status of the primary 
carcinoma. Using highly quantified assays for steroid receptor status that have received 
FDA approval ([58], DuPont 1988 PR Assay Kit, Abbott 1988 ER-EIA monoclonal assay, 
DuPont 1989 ER Assay Kit, Abott 1998 PGR-EIA monoclonal assay), cutoff values were 
utilized as reported earlier (e.g., [11, 57, 58]). An adjusted p-value of < 0.30 was employed 
as the discovery cut-off for significance as described previously [47].  
Results of analyses are displayed in which either ER or PR protein was measured 








measured by radio-ligand binding, it was observed that protein content of both uPA and 
uPAR were elevated in receptor positive carcinomas compared to those of receptor 
negative carcinomas (Figure 2 a-b and d-e).  In contrast, it was observed that protein 
content of uPAR was significantly elevated in ER- cancer biopsies compared to those 
ER+ specimens as measured by EIA (Figure 2h). Furthermore, protein levels of PAI-1 
were significantly elevated in either ER or PR negative cancers measured by EIA 
compared to receptor positive cancers (Figure 2 i,l).  
For each relationship, Violin plots juxtaposed distributions of uPA, uPAR or PAI-1 
expression values of either ER+ vs ER- or PR+ vs PR- primary breast cancers to examine 
potential regulation by these sex steroid hormones. Distributions were compared using 
an unpaired independent two-sample Mann-Whitney-Wilcoxon test. Plots display the 
kernel of the distribution of log uPA, uPAR or PAI-1 expression for either ER or PR 
subtypes from breast carcinomas. Median of log relative expression is indicated by a 
white circle and the interquartile range is denoted with a black bar. 
 
Figure 2. Relationship of biomarker protein status of the uPA system with ER or PR status 
of the primary carcinoma. Steroid receptor protein content (ER or PR) in plots a-f was 
determined by radio-ligand binding, and content in plots g-l was assessed by EIA. 





























3.3  |  Assessment of biomarker protein status as a function of HER2 protein status 
of the primary breast carcinoma  
 
 To assess the relationship between HER2 protein status of a primary breast 
carcinoma and uPA system biomarker, violin plots were constructed (Figure 3). An 
adjusted p-value of < 0.30 was employed as the cutoff value for significance. Our 
analyses indicated that HER2 status of the primary breast cancer was not related to 
protein content of either uPA, uPAR or PAI-1.  
 
Figure 3. Violin plots of protein biomarker content of urokinase plasminogen activator 
system members comparing distributions by HER2 status. Breast carcinomas were 
classified as either HER2+ or HER2- according to cutoff values for measurements 
obtained from either NEN/DuPont or TRITON assays as described in the Methods & 
Materials.   
 
 
3.4  |  Analysis of biomarker gene expression of the uPA pathway members as a 
function of ER or PR protein status of the primary breast carcinoma 
  
 Since ER is used routinely as a biomarker for prediction of breast cancer 








expression of either uPA, uPAR, PAI-1 or PAI-2 genes was examined through 
construction of Violin plots according to ER+ or ER- status of the primary lesion (Figure 
4). An adjusted p-value of < 0.30 was employed as a discovery cut-off for significance 
(e.g., [47]). Note that relative gene expression was estimated using LCM-procured breast 
carcinoma cells as described in Methods & Materials. These analyses revealed that 
expression of the uPA gene was significantly elevated in ER- cells compared to ER+ cells 
(Figure 4a). Analyses also indicated that expression of either uPAR or PAI-2 genes was 
significantly elevated in ER- breast cancer cells compared to ER+ cells at an adjusted p-
value of < 0.001 (Figure 4b and d). Expression of PAI-1 gene was not significantly 
expressed in regard to ER status of the primary lesion.  
 In addition, PR status of the primary lesion was evaluated in relation to expression 
of each candidate gene in LCM-procured cells. Therefore, Violin plots of PR+ and PR- 
lesions were constructed in relation to relative gene expression of each gene of interest 
(Figure 4). Analyses indicated that expression of uPA and its respective receptor, uPAR, 
were significantly elevated in PR- lesions (Figure 4 e-f). In comparison to PR+ cells, 
elevated expression of both PAI-1 and PAI-2 genes was detected in PR- breast cancer 
cells (Figure 4 g-h).  
 
Figure 4. Violin plots utilizing relative expression of genes of the uPA system estimated 
by microarray compared to either ER or PR status of the breast primary lesion for 247 
patients. Breast carcinomas were classified as either ER+ or ER- and either PR+ or PR- 




To determine if there is a relationship between either ER or PR protein levels in a 
primary lesion and relative expression of each gene of interest, scatter plots were 
constructed. Total ER or PR protein content (fmol /mg P) of each primary breast 
carcinoma was plotted as a function of relative expression for each gene of interest 
















expression in LCM-procured cells, determination of these relationships was possible with 
each of the four members of the plasminogen activator system.  
 Representative analyses of statistically significant analyses are shown in Figure 5. 
These data indicated a negative relationship between ER protein content and relative 
expression of uPA, uPAR and PAI-2 genes that was statistically significant (Figure 5 a-
c). When the relationship between PR protein content of the cancer biopsies was 
examined in relation to expression of each candidate biomarker, expression of uPAR and 
PAI-2 genes were significant (Figure 5d-e). 
 
Figure 5. Relationship of ER protein versus candidate gene expression a-c)  and PR 
protein content in relation to relative expression of candidate genes d-e). Of the 8 possible 
relationships of gene expression to steroid receptor status, only 5 exhibited statistical 
significance. Representative relationships of ER protein versus candidate gene 
expression (a-c) and PR protein content in relation to relative expression of candidate 








3.5  |  Interrelationships of relative gene expression of uPA, uPAR, PAI-1 and PAI-2 
as a function of HER2 protein status of the primary breast carcinoma  
 
 The HER2/neu protein status of a primary breast cancer is considered with ER and 
PR as a biomarker for prediction of breast cancer outcome and selection of treatment 
regimen [10, 15, 69]. Relative expression of each gene of members of the urokinase 
plasminogen activator system determined by microarray was evaluated in relationship to 
HER2 protein status (Figure 6). Analyses indicated that HER2 status of the primary breast 
cancer was not significantly related to expression of any of the four candidate genes 
analyzed.   
 
 
a b c 
d e  
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Figure 6. Representative violin plots utilizing microarray expression of genes of the uPA 
system comparing HER2 protein status for 45 patients. Breast carcinomas were classified 
as either HER2+ (n=28) or HER2- (n=17) with measurements obtained from either 
NEN/DuPont or TRITON assays as described in Materials & Methods.  
 
 
3.6  |  Biomarker gene expression of the LCM-procured carcinoma cells as a 










 Since the menopausal status of breast cancer patients is a clinically useful 
management parameter, Violin plots were created to examine the relative expression of 
each candidate gene in LCM-procured carcinoma cells and menopausal status of patients 
(Figure 7). Violin plots were constructed for each gene of interest according to 
premenopausal or postmenopausal status and an adjusted p-value of < 0.30 was 
employed as the discovery cutoff. Patients who were 54 years of age or younger at the 
time of biopsy were classified as premenopausal. Notably, expression of uPAR gene was 
significantly elevated in premenopausal patients at an adjusted p-value of < 0.30 (Figure 
7b).  
 
Figure 7. Violin plots comparing microarray expression levels of each gene of interest in 
LCM-procured breast carcinomas of either premenopausal (n=102) or postmenopausal 





3.7  |  Relative expression of each biomarker gene in the uPA pathway as a function 
of nodal status of the patient    
 
Nodal status of a patient presenting with breast carcinoma is of critical importance 
to clinical management ( e.g.,[10, 38]) although not all node positive breast cancers 
exhibit early recurrence. Relative expression of each gene of the uPA system was 
estimated in LCM-procured carcinoma cells by microarray and plotted in relationship to 










set of Violin plot analyses, patients with 1 or more nodes exhibiting breast carcinoma were 
considered node positive (Figure 8). 
 
Figure 8. Violin plots utilizing relative expression of genes of the uPA system estimated 
by microarray in relationship to either positive or negative nodal status for 247 patients. 











Since nodal status of patients is also considered in different categories based upon 
different patterns of breast carcinoma progression, recurrence and other clinical 
outcomes (e.g., [9, 10, 38]) analyses were performed. Violin plots utilized relative 
expression of either uPA, uPAR, PAI-1 or PAI-2 genes estimated by microarray of RNA 
extracted from LCM-procured carcinoma cells plotted in relationship to nodal status, 
either negative (n=125), 1-3 positive nodes (n=69) or >3 positive nodes (n=53) as shown 
in Figure 9. 
Analyses indicated that the nodal status of a patient with breast carcinoma was not 
related to relative expression of either uPA, uPAR, PAI-1 or PAI-2 genes estimated by 
microarray of RNA extracted from LCM-procured carcinoma cells (Figure 9).  
 
Figure 9. Violin plots utilizing relative expression of genes of the uPA system estimated 
by microarray in relationship to either negative (n=125), 1-3 positive (n=69) or >3 positive 





3.8  |  Interrelationships of biomarker status of the primary breast carcinoma with  
expression of candidate genes known to be associated with cancer  
 
 From our previous studies of gene expression in primary breast carcinomas [18, 
19, 51, 58], 110 genes of interest have been identified whose expression we have 








between expression of candidate cancer-related genes and protein biomarker content 
were analyzed through construction of Violin plots (Figure 10). Relative gene expression 
estimated by qPCR, an adjusted p-value of < 0.30 employed for significance and 
biomarker cutoff values described previously were employed in these analyses. It was 
observed that MSX1 expression was significantly elevated in uPA+ cells (Figure 9a), 
whereas expression of RERG was elevated in uPA- carcinomas (Figure 9b). In contrast, 
results indicated that LRBA expression was significantly elevated in uPAR- carcinomas 
(Figure 9c). Subsequent analyses revealed that SIAT8A expression was significantly 
elevated in uPAR+ breast cancer (Figure 9d). When qPCR gene expression was 
examined in relation to PAI-1 status it was observed that elevated expression of COMT 
and TGFB1 was observed in PAI-1+ cells (Figure 9e,f).   
 
Figure 10. Violin plots of the qPCR expression levels of representative genes known to 
be associated with breast cancer as a function of plasminogen activator system protein 









Although the sample size was small (n=29), the expression of a number of genes 
previously reported to be associated with breast carcinomas was examined as a function 
of the relative expression of uPA, uPAR, PAI-1 and PAI-2 genes. Scatter plots of the 
genes identified from analyses shown in Figure 10 were constructed (Figure 11). None of 
the genes examined indicated their relative expression was associated with that of either 
uPA, uPAR or PAI-1 genes when a p-value of <0.05 was employed for significance.  
 
Figure 11. Scatter plots of relative expression of candidate cancer-assoicated genes 
identified in Figure 10 as a function of relative gene expression of members of the 
urokinase plasminogen activator system. Results shown represent microarray expression 















3.9 | Univariable Cox Regression Analyses of Relative Gene Expression According 
to ER and PR Status of LCM-procured Breast Carcinoma Cells 
 
 To determine the relationship between expression of each gene from microarray 
of the urokinase plasminogen activator system and steroid receptor status, Cox 
regression analyses of genes were performed with regard to ER or PR status of the 
primary breast cancer. An adjusted p-value of < 0.30 was selected for discovery (Tables 
3 and 4). Cox regressions revealed that expression of PAI-2 in carcinoma cells was 
significantly related to OS in ER+ breast cancers. In ER-breast cancers, uPAR expression 
was related to prediction of PFS whereas PAI-1 expression predicted OS. Furthermore, 
when carcinomas were classified according to PR status, uPA expression was 










cancers, expression of either uPAR or PAI-2 was related to prediction of PFS. Similarly, 
expression of either PAI-1 or PAI-2 was related to prediction of OS in PR- breast cancer 

















Table 3. Univariable Cox Regression Analyses of Relative Gene Expression 
According to ER Status of LCM-procured Breast Carcinoma Cells. Relative 
expression of each gene was utilized for ER+ patients (n=146); relative expression of 
each gene was utilized for ER- patients (n=101). 
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PFS/ER+ 
Gene Symbol β HR  95% CI (HR) p value 
Adjusted  
p-value 
 uPA 0.17 1.185 (0.93,1.51) 0.165 0.375 
 uPAR 0.14 1.153 (0.39,1.19) 0.421 0.561 
 PAI-1 0.07 1.068 (0.82,1.63) 0.660 0.660 
 PAI-2 -0.39 0.680 (0.8,1.43) 0.177 0.354 
OS/ER+ 
 uPA 0.21 1.231 (0.21,0.92) 0.168 0.335 
 uPAR 0.13 1.136 (0.92,1.66) 0.516 0.588 
 PAI-1 0.13 1.135 (0.77,1.67) 0.466 0.516 
 PAI-2 -0.83 0.437 (0.81,1.59) 0.030 0.122 
PFS/ER- 
Gene Symbol β HR  95% CI (HR) p value 
Adjusted  
p-value 
 uPA -0.08 0.923 (0.14,0.76) 0.535 0.753 
 uPAR -0.39 0.677 (0.85,1.61) 0.013 0.093 
 PAI-1 0.19 1.213 (0.59,1.53) 0.238 0.630 
 
PAI-2 0.06 1.061 (0.66,1.39) 0.454 0.614 
OS/ER- 
 uPA 0.10 1.105 (0.05,0.44) 0.488 0.554 
 uPAR -0.14 0.870 (0.86,1.86) 0.342 0.459 
 PAI-1 0.39 1.471 (0.51,1.45) 0.039 0.275 





Table 4. Univariable Cox Regression Analyses of Relative Gene Expression 
According to PR Status of LCM-procured Breast Carcinoma Cells. Relative 
expression of each gene was utilized for PR+ patients (n=151); relative expression of 
each gene was utilized for PR- patients (n=96). 
 40 
PFS/PR+ 
Gene Symbol β HR  95% CI (HR) p value 
Adjusted  
p-value  
uPA 0.25 1.286 (0.99,1.66) 0.055 0.221 
 uPAR 0.16 1.177 (0.87,1.58) 0.282 0.342 
 
PAI-1 0.12 1.128 (0.83,1.54) 0.443 0.443 
 
PAI-1 -0.16 0.853 (0.6,1.22) 0.384 0.404 
OS/PR+ 
 uPA 0.39 1.481 (1.07,2.05) 0.018 0.072 
 uPAR 0.21 1.232 (0.89,1.71) 0.213 0.426 
 PAI-1 0.10 1.102 (0.77,1.58) 0.600 0.657 
 PAI-2 -0.15 0.864 (0.57,1.3) 0.486 0.600 
PFS/PR- 
Gene Symbol β HR  95% CI (HR) p value 
Adjusted  
p-value 
 uPA -0.12 0.885 (0.55,1) 0.310 0.413 
 uPAR -0.30 0.737 (0.97,1.35) 0.048 0.191 
 PAI-1 0.05 1.054 (0.7,1.12) 0.725 0.725 
 PAI-2 0.13 1.143 (0.79,1.41) 0.109 0.218 
OS/PR- 
 uPA -0.02 0.982 (0.93,1.74) 0.894 0.894 
 uPAR -0.10 0.908 (0.98,1.4) 0.522 0.696 
 PAI-1 0.24 1.269 (0.67,1.22) 0.137 0.274 
 PAI-2 0.16 1.170 (0.76,1.28) 0.084 0.212 
 
 
4  |  Discussion   
  
Investigations reported in this thesis are focused on relationships of the 
biomarkers, uPA, uPAR and PAI-1 in primary breast cancer biopsies with other clinical 
features of the carcinomas (e.g., nodal status) and of the patients (e.g., menopausal 
status) to determine if there are alternative protein biomarker combinations (e.g., with 
either ER or PR status) that predict clinical outcomes (progression-free survival and/or 
overall survival) of breast carcinoma patients in an improved manner. In addition, I 
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compared previously reported gene expression results obtained by microarray of RNA 
extracted from LCM-procured breast carcinoma cells (e.g., [47-52, 58, 70]) with clinical 
outcomes and carcinoma-based parameters for the study populations of breast cancer 
patients. The analyses reported utilize de-identified results from retrospective studies of 
biomarker determinations and de-identified clinical outcomes that were collected 
previously and stored in our comprehensive databases. Investigations described here 
showing the combined clinical value of ER and PR determinations of the primary breast 
cancer biopsy with those for uPA, uPAR and PAI-1 protein content are an extension of 
our earlier report [58]. 
 One focus of cancer research in a modern context is to examine either the 
expression of genes or to quantify biomarkers of cancer associated members in regard 
to clinical and pathologic features [48, 56, 71]. Modern strategies such as the use of 
commercial genomic testing, have demonstrated clinical utility (e.g., MammaPrintTM, 
OncoTypeDXTM) for the management of breast cancer in addition to the use of 
chemotherapy agents [12, 13, 71]. Development of treatments and tests were due in part 
to investigations of cancer associated genes and proteins as it relates to patient 
characteristics. Thus, interrelationships between quantified content of uPA system 
proteins and clinical features such as patient age, and ER, PR or HER2 status of breast 
carcinoma patients were examined.   
 Results revealed that an increase of uPA, uPAR or PAI-1 protein content was not 
correlated with patient age. Relationships between other biomarkers for breast cancer 
(e.g., ER or PR protein) in intact tissue biopsies and patient age have exhibited 
associations for breast cancer patients, though the literature is conflicting (i.e., [72, 73]). 
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Similarly, our findings presented in Figure 2 established relationships between biomarker 
protein content of the uPA system and either ER or PR status of the primary carcinoma. 
Violin plots indicated either uPA or uPAR content was elevated in carcinomas when they 
also exhibited elevated levels of either ER or PR protein content as measured by radio-
ligand binding. However, when ER or PR content was determined by EIA, receptor 
negative carcinomas exhibited elevated levels of uPA content.  
Differences in relations of protein content and status (i.e., Figure 2 b/h) may be 
due to the type of assay employed despite utilization of standard cutoff values for both 
the radio-ligand binding and the EIA assay [57].  Literature reports evidence of a weak 
association of negative ER status and elevated uPA content in carcinomas were similar 
to our findings when ER was assessed by EIA [74, 75]. To extend our investigation of 
interrelationships between gene expression and proteins status, HER2 status was 
examined in relation to biomarker protein content. No relationships were detected 
between HER2 status and protein content of either uPA, uPAR or PAI-1 for our patient 
population.  
Interrelationship analyses utilized expression from microarray of LCM-procured 
breast carcinoma cells collected under stringent conditions. In addition, IMUBIND kits 
were employed to quantify uPA, uPAR and PAI-1 content using cellular extracts from 
heterogeneous tissue samples of breast cancer [26, 27, 53, 54]. Thus, results presented 
may reflect a heterogeneous tumor microenvironment which is composed of stromal 
elements [49, 74]. Largely, results of figures 1-3 indicated that biomarker protein content 
may be related to patient age and ER/PR status, but no relation with HER2 status was 
observed among our patient population.  
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 Established relationships have been reported between uPA, uPAR, PAI-1 content 
of a primary carcinoma and clinical features such as ER/PR status and outcomes [26, 27, 
53, 76].  However, few studies examined relationships for both protein content and gene 
expression of uPA system members within a unique patient population, such as that used 
in these investigations. Our exploratory and complementary analyses, described in in 
Figures 4-5, investigated gene expression results, collected from LCM-procured breast 
carcinoma cells, according to either ER, PR or HER2 status of the primary.  Additionally, 
expression of plasminogen activator inhibitor 2 (PAI-2) gene was incorporated due to 
limited research regarding its expression in breast cancer.  
Our results in Figure 4 largely parallel those of analyses displayed in plots g-l of 
Figure 2. Expression of either uPA, uPAR, PAI-1 or PAI-2 genes was significantly 
elevated in either ER- or PR- carcinomas similar to the observed elevation of protein 
content in receptor negative carcinomas (Figure 2) measured by EIA. Figure 5 delineated 
the extent of relationships between expression of each uPA system member and 
quantified ER or PR protein. Scatter plots revealed that expression of either uPA, uPAR 
or PAI-2 appear to be negatively correlated both ER and PR protein of the primary. 
Collectively, results of Figures 2, 4 and 5 largely indicate that increased protein content 
or expression of uPA system members is significantly associated with receptor negative 
carcinomas (i.e., ER- or PR-). Collective findings are in contrast to plots a-f of Figure 2 in 
which either uPA or uPAR protein content was elevated in ER+ cells determined by a 
radio-ligand binding assay.  
Nodal status and menopausal status, which are clinically relevant parameters, are 
documented as factors for prediction of clinical outcome, likelihood of recurrence and 
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clinical management strategies for patients with breast cancer [9, 10, 38, 73, 74]. 
Therefore, biomarker gene expression was examined as a function of menopausal status 
of patients with breast cancer. A noteworthy observation was elevation of uPAR 
expression in pre-menopausal status among our patient population. Elevation of uPAR 
content is associated with poor outcome [45], but few studies have examined expression 
of uPAR as a function of clinically relevant parameters. An elevation of expression in post-
menopausal patients compared to pre-menopausal may be a reflection of changes in ER 
and PR serum levels associated with menopause in women. This finding is indicative of 
a relationship menopausal status of breast cancer patients and uPAR, although our 
results warrant further investigation.  
  Similarly, nodal status of patients with breast cancer was examined according to 
gene expression of each uPA system member (Figures 8 and 9). Nodal status of each 
patient was classified in two different categories due to documented differential outcomes 
according to either status of nodes or number of nodes which are positive [9, 45]. A 
positive nodal status was designated as the presence of one or more nodes positive in 
figures 8, whereas nodal status was classified according to total number of nodes in figure 
9. Collectively, PAI-1 was elevated in node positive breast carcinomas whereas the 
alternate classification did not provide statistically significant differences (Figure 9). In the 
context of a clinical setting, it may be useful to assign positive nodal status as one or more 
nodes exhibiting breast cancer for assessment of PAI-1. However, classification of status 
according to the number of nodes that are positive holds strong clinical utility for the 
prediction of early recurrence and clinical outcome [38, 77]. 
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Interrelationships of qPCR expression of a number of genes reported to be 
associated with breast cancer outcomes was studied as a function of biomarker status. 
In addition, the uPA system has reported roles in processes of inflammation, 
angiogenesis, embryogenesis, wound healing, cellular apoptosis tumor migration and 
angiogenesis [22-24]. Expression of genes such as TGFB1 or LRBA was significantly 
associated with either PAI-1 or uPAR status. Similarly, significant differences in 
expression of genes MSX1, RERG, SIAT8A and COMT according to biomarker status 
was observed.   
The status of either uPA, uPAR or PAI-1 protein content was assigned according 
to standard cut-off values provided by IMUBINDTM kits whereas expression of each gene 
was estimated via qPCR on intact carcinoma tissue sections [52]. Analyses in Figure 11 
employed expression obtained from microarray analysis of LCM-procured breast 
carcinoma cells in which significant interrelationships were not observed. Thus, the 
clinical utility of our preliminary findings warrants additional investigation in the context of 
the microenvironment of breast carcinomas. Differences in expression patterns for the 
genes of interest could be a reflection of the genomic profile of a heterogeneous breast 
tissue sample (i.e., collection of qPCR expression) compared to that of isolated carcinoma 
cells [49].  
Investigations described in this thesis were focused on evaluating the combined 
clinical value of ER and PR protein determinations of the primary breast carcinoma biopsy 
with those for uPA, uPAR and PAI-1 protein content to improve breast cancer 
management. Our studies also included examination of the expression of the genes for 
each of the biomarkers under consideration. 
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 Expression of PAI-2 gene was significantly related to overall survival of patients 
with ER+ breast cancers. In ER- carcinomas, expression of either uPAR or PAI-1 was 
related to PFS or OS, respectively. In contrast, literature reports have focused on protein 
content and indicate PAI-2 level is related to increased prognosis for breast cancer 
patients, whereas other studies have reported no significance for the use of PAI-2 level 
as a determinant of clinical outcome [78, 79]. Additionally, Gelder et al. [80] analyzed PAI-
2 level of cytosols prepared from ER+ primary breast cancers and discovered a significant 
relationship between high PAI-2 level and length of response to Tamoxifen (i.e., first-line 
therapy for recurrent breast cancer). Thus, our findings establishing the relationship 
between uPAR, PAI-1 and PAI-2 genes with clinical outcomes of patients with breast 
cancers exhibiting various ER status support the concept that estrogen levels are involved 
in regulation of these biomarkers.  
 Kotzsch et al. [81] examined uPAR gene expression obtained from microarray in 
breast tumor specimens for invasive ductal carcinomas. It was reported that elevated 
uPAR gene expression levels in tumor cells, and not from stromal cells, was predictive of 
PFS. Our findings support the work of Kotzsch et al. [81] and identify the prognostic value 
of uPAR gene expression in ER- carcinomas. In breast cancer patients, it is widely known 
that elevated PAI-1 level is associated with poor OS, whereas few studies have evaluated 
PAI-1 gene expression. Our analyses identified a relationship between PAI-1 gene 
expression and OS for ER- patients. Since ER- patients are not candidates for traditional 
treatments (i.e., SERM, Raloxifene, Tamoxifen), further examination of PAI-1 gene 
expression may serve as a strategy for breast cancer management as evidenced by our 
findings. In PR+ patients, uPA gene expression obtained from microarray of LCM-
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procured breast carcinoma cells was significantly related to prediction of either PFS or 
OS. In PR- patients, PAI-2 expression collected from LCM-procured breast carcinoma 
cells was predictive of PFS and OS. 
  Current guidelines for the management of primary breast carcinomas instruct 
clinicians to utilize analyses of ER, PR and HER2 protein levels collectively to assess risk 
of recurrence and therapy selection [15, 69]. The results of the investigations reported in 
this thesis strongly suggest that consideration of combinations of results from ER or PR 
protein content with the measurements of either uPA, uPAR or PAI-1 protein levels of a 
primary breast cancer biopsy provide improvements in assessing a patient’s clinical 
outcome. Furthermore, our collective analyses of expression of genes, uPA, uPAR, PAI-
1 and PAI-2 as well as those for ESR1 (gene expressing ER mRNA and protein) and 
PGR (gene for expressing PR mRNA and protein) using LCM-procured breast carcinoma 
cells, indicated relationships between levels of biomarker mRNA and disease-free 
progression and overall survival of patients.  
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